Anti-inflammatory and Anti-aging cosmetic for use after aesthetic medical procedure

Abstract

The present invention provides an anti-inflammatory and anti-aging cosmetic for use after an aesthetic medical procedure, pertains to the field of cosmetics, and specifically relates to a liquid composition. The liquid composition is prepared from a functional agent, an auxiliary agent, and water, and can be used in cosmetics. The auxiliary agent further comprises a thickener, a humectant, and a preservative. The functional agent comprises at least an active substance, and the active substance comprises at least one of acetyl hexapeptide-8, oligopeptide-1, dipeptide diaminobutyroyl benzylamide diacetate, carnosine, palmitoyl tripeptide-1, ACE liposomes, bifida ferment lysate, and a cell lysate. The functional agent may further comprise an active agent. The obtained liquid composition is non-cytotoxic, safe, promotes cell proliferation, has a good anti-inflammatory effect and a good anti-aging effect, is non-irritating to the skin, and, when used after an aesthetic medical procedure, has a good anti-inflammatory effect.

Description

An anti-inflammatory and anti-aging cosmetic that can be used after cosmetic procedures. Technical Field

[0001] This invention belongs to the field of cosmetics, specifically relating to an anti-inflammatory and anti-aging cosmetic that can be used after cosmetic procedures. Background Technology

[0002] With people's ever-growing pursuit of beauty, the field of medical aesthetics has ushered in unprecedented development opportunities. Various minimally invasive cosmetic techniques have emerged like mushrooms after rain, among which mesotherapy and phototherapy are highly favored due to their significant effects. These techniques, through different mechanisms of action, effectively address a range of skin problems such as pigmentation, aging, acne, and dryness, rejuvenating the skin. However, while bringing beauty, minimally invasive medical aesthetic procedures inevitably have some impact on the skin barrier. As an important protective layer of the human body, damage to the skin barrier not only affects the health of the skin but can also lead to various skin problems. For some patients with sensitive skin, the harm caused by the release of inflammatory factors during the repair process is more lasting. Therefore, using barrier repair products after minimally invasive medical aesthetic procedures becomes an indispensable step. At the same time, inflamed skin is more susceptible to external stimuli than normal skin, inducing inflammation, releasing free radicals to participate in the inflammation and glycation processes, forming a vicious cycle of inflammation-glycation-oxidation, leading to more premature aging. Therefore, anti-aging effects for inflamed skin are just as important as anti-inflammatory repair. However, the Class II dressings commonly used in post-cosmetic procedures primarily function as a physical barrier by forming a protective layer on the wound surface. CN117085174A discloses a liquid dressing for post-cosmetic procedure wound care and its preparation method, but Class II dressings lack pharmacological efficacy and are not biodegradable or absorbable. The use of large-molecule moisturizing substances is limited, as they cannot be truly absorbed through the skin. After rapid wound healing, the therapeutic effect of Class II dressings becomes less significant. Furthermore, conventional anti-aging cosmetics lack research on their suitability for the inflammatory phase following cosmetic procedures.

[0003] The post-operative repair process in cosmetic dermatology is divided into three stages. The first is the acute inflammatory phase, occurring 24 hours post-surgery. Within minutes of tissue injury, immune cells rapidly infiltrate the wound, with neutrophils and macrophages being the primary effector cells. These immune cells release various cytokines and chemokines, recruiting cells from the bloodstream and the wound periphery into the local wound area. Simultaneously, the secreted cytokines further promote cell proliferation at the injury site. In addition, immune cells secrete various proteases and reactive oxygen species (ROS) to resist pathogen invasion and clear damaged cells. Although early inflammatory responses are beneficial for wound healing, multiple studies have shown that an increase in the number of immune cells at the injury site or a prolonged inflammatory response can disrupt the repair process, ultimately leading to chronic non-healing wounds or pathological scarring. This is mainly because the continuous generation of ROS at the injury site damages cell structure and function, disrupting the normal skin repair process. Two to ten days after skin injury, new tissue begins to form, and the repair enters the proliferative phase. This stage mainly includes angiogenesis, granulation tissue formation, and re-epithelialization. Angiogenesis is crucial for wound repair. Macrophages and damaged endothelial cells release FGF-2 and VEGF, promoting angiogenesis. Subsequently, capillary budding infiltrates the damaged area, forming granulation tissue with fibroblasts and immune cells, providing nutrients and oxygen for cellular metabolism. Finally, growth factors such as EGF and TGF-β stimulate the proliferation and migration of keratinocytes at the wound edge, enabling re-epithelialization of the damaged dermis. After re-epithelialization is complete, keratinocytes differentiate, restoring the epidermal barrier function. Simultaneously, dermal fibroblasts proliferate and migrate to the damaged area, producing abundant extracellular matrix. Towards the end of this stage, growth factors (TGF-β) or mechanical pressure stimulate some fibroblasts to differentiate into myofibroblasts, which express actin (α-smooth) to promote wound contraction. The third stage is the tissue remodeling period, generally occurring 2-3 weeks after injury and lasting for many years. In this stage, the signals activating the injury gradually weaken. Once re-epithelialization is complete, keratinocytes cease proliferation and migration and immediately begin differentiation. Blood vessels within the newly formed tissue gradually mature, forming a functional network. Most endothelial cells, inflammatory cells, fibroblasts, and myofibroblasts undergo apoptosis or withdraw from the wound site. Granulation tissue formed during the early repair process is gradually replaced by newly formed collagen-rich dermal matrix. Notably, normal skin tissue is primarily composed of type III collagen forming a basket-weave structure, while the damaged area remodels with coarser type I collagen, forming a dense, parallel structure. Epidermal appendages, such as hair follicles and sebaceous glands, generally cannot regenerate during this process. Therefore, the newly formed tissue usually differs from healthy tissue, manifesting as scarring, characterized primarily by decreased elasticity and tensile strength. Summary of the Invention

[0004] This invention combines the usage scenarios and functional defects of Class II excipients and conventional cosmetics, and proposes the concept of cosmetic-medical device combination. Class II sterile dressing products are used during the acute inflammatory period after medical aesthetic procedures to inhibit the occurrence of acute inflammation and promote wound healing. This is then combined with gentle and soothing anti-aging products to meet anti-aging needs.

[0005] The purpose of this invention is to provide a non-cytotoxic, safe, cell-proliferation-promoting, anti-inflammatory, and anti-aging cosmetic product that can be used after cosmetic procedures.

[0006] The technical solution adopted by the present invention to achieve the above objectives is as follows:

[0007] A liquid complex comprises: an active ingredient and water, wherein the active ingredient content in the liquid complex is 0.003-6.0 wt%; the active ingredient includes an active ingredient, which includes at least one selected from acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, palmitoyl tripeptide-5, ACE liposomes, bifida ferment lysate, and lysate. The liquid complex of this invention is a product with both anti-inflammatory and anti-aging effects, suitable for daily skincare and post-medical aesthetic procedures. It can compensate for the anti-aging effects of second-generation dressings while also satisfying the gentle anti-inflammatory effects of cosmetics. The formulation is simplified, and the manufacturing process is easy.

[0008] Preferably, the liquid complex further includes a thickener, which includes at least one of carbomer, xanthan gum, and sclerotinia gum, and the content of the thickener in the liquid complex is 0.01-1.0 wt%.

[0009] Preferably, the liquid complex further includes a humectant, which includes at least one of glycerin, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, carboxymethyl cellulose, and chitosan, and the content of the humectant in the liquid complex is 1-20 wt%.

[0010] Preferably, the liquid complex further includes a preservative, which is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.1-1.0 wt%.

[0011] Preferably, the active ingredient further includes an active agent, which includes a succinate derivative made from 2-aminoethanol hydrogen sulfate and maleate, and the maleate is made from trimethylolpropane and maleic anhydride. This invention reveals that the succinate derivative can be combined with the active ingredient for use, and with the help of other excipients, the anti-aging and anti-inflammatory effects of the resulting liquid complex can be improved. It exhibits no cytotoxicity, good safety, and no skin irritation.

[0012] More preferably, the content of the surfactant in the liquid complex is 0.003-1.0 wt%; or,

[0013] The content of active ingredients in the liquid complex is 0.003-5.0 wt%.

[0014] More preferably, in the preparation of maleic ester, trimethylolpropane and maleic anhydride are mixed and reacted to obtain maleic ester, wherein the amount of trimethylolpropane used is 50-150 wt% of maleic anhydride.

[0015] More preferably, in the preparation of the succinate derivative, 2-aminoethanol hydrogen sulfate and maleate are mixed in an aqueous ethanol solution containing sodium hydroxide to react and obtain the succinate derivative; the amount of 2-aminoethanol hydrogen sulfate used is 20-30 wt% of maleate.

[0016] This invention discloses the use of the above-mentioned liquid complex in the preparation of anti-inflammatory cosmetics and / or anti-aging cosmetics and / or non-irritating products.

[0017] Preferably, in the preparation of maleic ester, trimethylolpropane is added to maleic anhydride at 60-80°C, and the reaction is carried out at 85-95°C for 2-8 hours. After the reaction is completed, maleic ester is obtained.

[0018] More preferably, in the preparation of maleic esters, the amount of trimethylolpropane used is 50-150 wt% of maleic anhydride.

[0019] Preferably, in the preparation of the succinate derivative, sodium hydroxide and 2-aminoethanol hydrogen sulfate are added to deionized water and stirred and mixed. Then, maleic acid ester and ethanol are added at 30-50°C and reacted for 2-8 hours. After the reaction is completed, the precipitate is cooled and precipitated. The precipitate is filtered, washed, and distilled under reduced pressure to obtain the succinate derivative.

[0020] More preferably, in the preparation of succinate derivatives, the amount of sodium hydroxide used is 30-50 wt% of deionized water.

[0021] More preferably, in the preparation of the succinate derivative, the amount of 2-aminoethanol hydrogen sulfate used is 40-60 wt% of deionized water.

[0022] More preferably, in the preparation of the succinate derivative, the amount of 2-aminoethanol hydrogen sulfate used is 20-30 wt% of maleate.

[0023] More preferably, in the preparation of the succinate derivative, the amount of anhydrous ethanol used is 100-200 wt% of maleate.

[0024] This invention discloses a method for preparing a liquid complex, comprising: adding a thickener to water, then adding a humectant and a preservative, homogenizing at 70-90°C for 2-10 minutes, cooling to 20-50°C after homogenization, then adding an active ingredient, stirring and mixing evenly, and cooling to room temperature to obtain the liquid complex.

[0025] Preferably, the active ingredient comprises an active ingredient, which includes at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposomes, Bifida ferment lysate, and lysate, and the content of the active ingredient in the liquid complex is 0.003-5.0 wt%.

[0026] Preferably, the thickener includes at least one of carbomer, xanthan gum, and sclerotium gum, and the content of the thickener in the liquid complex is 0.01-1.0 wt%.

[0027] Preferably, the humectant includes at least one of glycerin, 1,2-pentanediol, dipropylene glycol, carboxymethyl cellulose, and chitosan, and the content of the humectant in the liquid complex is 1-20 wt%.

[0028] Preferably, the preservative is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.1-1.0 wt%.

[0029] Preferably, the remaining reagent in the liquid complex is water.

[0030] Preferably, the active ingredient further includes an active agent, and the content of the active agent in the liquid complex is 0.003-1.0 wt%. The active agent includes succinate derivatives and / or 1,2-propanediol alginate. The present invention may also add 1,2-propanediol alginate as an active agent. Using 1,2-propanediol alginate and succinate derivatives as active agents, the resulting liquid complex, under the action of the active ingredients and excipients, exhibits superior anti-aging and anti-inflammatory effects, is non-cytotoxic, has good safety, and is non-irritating to the skin.

[0031] More preferably, the active agent includes a succinate derivative, and the content of the succinate derivative in the liquid complex is 0.003-0.5 wt%.

[0032] More preferably, the activator also includes alginate-1,2-propanediol ester, and the content of alginate-1,2-propanediol ester in the liquid complex is 0.003-0.5 wt%.

[0033] Without affecting the effectiveness of the invention, harmless reagents such as EDTA, disodium EDTA, and amino acids may also be added. Amino acids include arginine and other amino acids.

[0034] This invention utilizes an active ingredient, excipients, and water to prepare a liquid complex suitable for use in cosmetics. The excipients include thickeners, humectants, and preservatives. The active ingredient in this invention includes at least one active ingredient selected from the following: acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposomes, bifida ferment lysate, and lysate. The liquid complex containing these active ingredients exhibits excellent anti-inflammatory and anti-aging effects. Furthermore, this invention can also incorporate additional active ingredients; the use of these active ingredients, combined with the action of the active ingredients and excipients, results in a liquid complex with even better effects. The liquid complex obtained by this invention is non-cytotoxic, safe, promotes cell proliferation, has good anti-inflammatory and anti-aging effects, is non-irritating to the skin, and provides good anti-inflammatory effects after cosmetic procedures. Therefore, this invention is a non-cytotoxic, safe cosmetic that promotes cell proliferation, has good anti-inflammatory and anti-aging effects, is non-irritating to the skin, and provides good anti-inflammatory effects after cosmetic procedures, and can be used for anti-inflammatory and anti-aging purposes after cosmetic procedures. Attached Figure Description

[0035] Figure 1 shows the expression results of cellular inflammatory factors.

[0036] Figure 2 shows the expression results of cellular inflammatory factors.

[0037] Figure 3 shows the expression results of cellular inflammatory factors.

[0038] Figure 4 shows the expression results of cellular inflammatory factors.

[0039] Figure 5 shows the expression of inflammatory factors in MIF.

[0040] Figure 6 shows the results of relative gene expression levels.

[0041] Figure 7 shows the results of relative gene expression levels.

[0042] Figure 8 shows the results of relative gene expression levels.

[0043] Figure 9 shows the results of relative gene expression levels.

[0044] Figure 10 shows the relative gene expression levels of NFE2L2. Detailed Implementation

[0045] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0046] The concepts involved in this application will first be described with reference to the accompanying drawings. It should be noted that the following descriptions of various concepts are only for the purpose of making the content of this application easier to understand and do not constitute a limitation on the scope of protection of this application; furthermore, the embodiments and features in the embodiments of this application can be combined with each other unless otherwise specified. This application will now be described in detail with reference to the accompanying drawings and embodiments.

[0047] Example 1: A method for preparing a liquid complex

[0048] Preparation of the liquid complex: The thickener was added to water, followed by the humectant and preservative. The mixture was homogenized at 80°C for 3 minutes. After homogenization, the mixture was cooled to 40°C. The active ingredient was then added, and the mixture was stirred until homogeneous. The mixture was then cooled to room temperature to obtain the liquid complex. The thickener is carbomer, the humectant is glycerin, the preservative is raspberry ketone system, and the active ingredients include ACE liposomes, acetyl hexapeptide-8, snake venom-like peptides, and Bifida ferment lysate. The ACE liposomes are Lips-014 ACE liposomes. The liquid complex contains 0.24 wt% thickener, 8 wt% humectant, 0.35 wt% preservative, 1.5 wt% ACE liposomes, 0.005 wt% acetyl hexapeptide-8, 0.01 wt% snake venom-like peptides, and 1.5 wt% Bifida ferment lysate. The remainder is water.

[0049] The liquid complex prepared in Example 1 consisted of an active ingredient, a thickener, a humectant, a preservative, and water. The active ingredient included an active ingredient, specifically ACE liposomes, acetyl hexapeptide-8, a snake venom-like peptide, and a Bifida ferment lysate. The ACE liposomes were Lips-014 ACE liposomes, and the liquid complex contained 1.5 wt% ACE liposomes, 0.005 wt% acetyl hexapeptide-8, 0.01 wt% snake venom-like peptide, and 1.5 wt% Bifida ferment lysate. The thickener was carbomer, and the liquid complex contained 0.24 wt% carbomer. The humectant was glycerol, and the liquid complex contained 8 wt% humectant. The preservative was a raspberry ketone system, and the liquid complex contained 0.35 wt% preservative. The remainder was water.

[0050] Example 2: A method for preparing a liquid complex

[0051] The difference between this embodiment and Example 1 is that the active ingredient also includes an activator. The activator is a succinate derivative. The content of the succinate derivative in the liquid complex is 0.009 wt%.

[0052] Preparation of maleic ester: Trimethylolpropane was added to maleic anhydride at 70°C, and the reaction was carried out at 90°C for 4 hours. After the reaction was completed, maleic ester was obtained. The amount of trimethylolpropane used was 100 wt% of maleic anhydride.

[0053] Preparation of succinate derivatives: Sodium hydroxide and 2-aminoethanol hydrogen sulfate were added to deionized water and stirred. Then, maleic ester and ethanol were added at 40°C, and the reaction was allowed to proceed for 4 hours. After the reaction was complete, the precipitate was cooled and precipitated. The precipitate was filtered, washed, and distilled under reduced pressure to obtain the succinate derivatives. The amount of sodium hydroxide used was 40 wt% of deionized water, the amount of 2-aminoethanol hydrogen sulfate used was 50 wt% of deionized water, the amount of 2-aminoethanol hydrogen sulfate used was 25 wt% of maleic ester, and the amount of anhydrous ethanol used was 150 wt% of maleic ester.

[0054] Example 2 prepared a liquid complex comprising: an active ingredient, a thickener, a humectant, a preservative, and water. The active ingredient included an active ingredient and a activator. The active ingredient was ACE liposomes, acetyl hexapeptide-8, a snake venom-like peptide, and a Bifida ferment lysate. The ACE liposomes were Lips-014 ACE liposomes, and the liquid complex contained 1.5 wt% ACE liposomes, 0.005 wt% acetyl hexapeptide-8, 0.01 wt% snake venom-like peptide, and 1.5 wt% Bifida ferment lysate. The activator was a succinate derivative, and the liquid complex contained 0.009 wt% succinate derivative. The thickener was carbomer, and the liquid complex contained 0.24 wt% carbomer. The humectant was glycerol, and the liquid complex contained 8 wt% humectant. The preservative was a raspberry ketone system, and the liquid complex contained 0.35 wt% preservative. The balance was water.

[0055] Example 3: A method for preparing a liquid complex

[0056] The difference between this embodiment and Example 1 is that the active ingredient also includes an activator. The activator is a succinate derivative. The content of the succinate derivative in the liquid complex is 0.03 wt%.

[0057] Example 3 describes the preparation of a liquid complex comprising: an active ingredient, a thickener, a humectant, a preservative, and water. The active ingredient includes an active ingredient and a activator. The active ingredient is ACE liposomes, acetyl hexapeptide-8, a snake venom-like peptide, and a Bifida ferment lysate. The ACE liposomes are Lips-014 ACE liposomes, and the liquid complex contains 1.5 wt% ACE liposomes, 0.005 wt% acetyl hexapeptide-8, 0.01 wt% snake venom-like peptide, and 1.5 wt% Bifida ferment lysate. The activator is a succinate derivative, and the liquid complex contains 0.03 wt% succinate derivative. The thickener is carbomer, and the liquid complex contains 0.24 wt% carbomer. The humectant is glycerol, and the liquid complex contains 8 wt% humectant. The preservative is a raspberry ketone system, and the liquid complex contains 0.35 wt% preservative. The balance is water.

[0058] Example 4: A method for preparing a liquid complex

[0059] The difference between this embodiment and Example 3 is that the active agent further includes 1,2-propanediol alginate. The content of 1,2-propanediol alginate in the liquid complex is 0.003 wt%.

[0060] Example 4 describes the preparation of a liquid complex consisting of an active ingredient, a thickener, a humectant, a preservative, and water. The active ingredient includes an active ingredient and a surfactant. The active ingredient is ACE liposomes, acetyl hexapeptide-8, a snake venom-like peptide, and a Bifida ferment lysate. The ACE liposome is Lips-014. The liquid complex contains 1.5 wt% ACE liposomes, 0.005 wt% acetyl hexapeptide-8, 0.01 wt% snake venom peptide, and 1.5 wt% Bifida ferment lysate. The active agents are succinate derivatives and 1,2-propanediol alginate, with 0.03 wt% succinate derivatives and 0.003 wt% alginate in the liquid complex. The thickener is carbomer, comprising 0.24 wt% of the liquid complex. The humectant is glycerol, comprising 8 wt% of the liquid complex. The preservative is a raspberry ketone system, comprising 0.35 wt% of the liquid complex. The balance is water.

[0061] Example 5: A method for preparing a liquid complex

[0062] The difference between this embodiment and Example 3 is that the active agent further includes 1,2-propanediol alginate. The content of 1,2-propanediol alginate in the liquid complex is 0.01 wt%.

[0063] Example 5 prepared a liquid complex consisting of an active ingredient, a thickener, a humectant, a preservative, and water. The active ingredient included an active ingredient and a surfactant. The active ingredient was ACE liposomes, acetyl hexapeptide-8, a snake venom-like peptide, and a Bifida ferment lysate. The ACE liposomes were Lips-014. The liquid complex contains 1.5 wt% ACE liposomes, 0.005 wt% acetyl hexapeptide-8, 0.01 wt% snake venom peptide, and 1.5 wt% Bifida ferment lysate. The active agents are succinate derivatives and 1,2-propanediol alginate, with 0.03 wt% succinate derivatives and 0.01 wt% alginate in the liquid complex. The thickener is carbomer, comprising 0.24 wt% of the liquid complex. The humectant is glycerol, comprising 8 wt% of the liquid complex. The preservative is a raspberry ketone system, comprising 0.35 wt% of the liquid complex. The balance is water.

[0064] Comparative Example 1: A method for preparing a liquid complex

[0065] The difference between this comparative example and Example 2 is that the content of the succinate derivative in the liquid complex is 0.001 wt%.

[0066] The liquid complex prepared in Comparative Example 1 consisted of an active ingredient, a thickener, a humectant, a preservative, and water. The active ingredients include active ingredients and activators. The active ingredients are ACE liposomes, acetyl hexapeptide-8, snake venom-like peptides, and Bifida ferment lysate. The ACE liposomes are Lips-014 ACE liposomes, with 1.5 wt% of ACE liposomes, 0.005 wt% of acetyl hexapeptide-8, 0.01 wt% of snake venom-like peptides, and 1.5 wt% of Bifida ferment lysate in the liquid complex. The activators are succinate derivatives, with 0.001 wt% of succinate derivatives in the liquid complex. The thickener is carbomer, with 0.24 wt% of carbomer in the liquid complex. The humectant is glycerol, with 8 wt% of humectant in the liquid complex. The preservative is a raspberry ketone system, with 0.35 wt% of preservative in the liquid complex. The balance is water.

[0067] Comparative Example 2: A method for preparing a liquid complex

[0068] The difference between this comparative example and Example 2 is that no active ingredient was added to the liquid complex.

[0069] The liquid complex prepared in Comparative Example 1 consisted of an active agent, a thickener, a humectant, a preservative, and water. The active agent included an active agent, a succinate derivative, with the succinate derivative comprising 0.009 wt% of the liquid complex; a carbomer thickener comprising 0.24 wt% of the liquid complex; glycerin as a humectant comprising 8 wt% of the liquid complex; and a raspberry ketone system as a preservative comprising 0.35 wt% of the liquid complex. The balance was water.

[0070] In the selection of components for the liquid complex in this invention, without affecting the technical effect of this invention, glycerol, disodium EDTA, raspberry ketone, 1,2-hexanediol, xanthan gum, 1,2-pentanediol, carbomer, carboxymethyl deacetylated chitosan, arginine, dipropylene glycol, ACE liposomes, acetyl hexapeptide-8, snake venom-like peptide, oligopeptide-1, palmitoyl tripeptide-5, carnosine, and bifida ferment lysate can be selected arbitrarily.

[0071] Experimental example:

[0072] 1. Cytotoxicity test

[0073] This invention tested the cytotoxicity of the liquid complex prepared in Example 1. The liquid complex from Example 1 was mixed with culture medium to prepare eight test groups with different volume percentages: 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125%. A blank control group and a positive control group were set up. The blank control group consisted of culture medium, and the positive control group consisted of culture medium supplemented with 10% DMSO. The test groups, blank control group, and positive control group were brought into contact with test cells. The in vitro cytotoxicity was evaluated by testing the effect on cell growth inhibition, thus examining the safety of the compound as a human contact material. The test cells were human immortalized keratinocytes (HaCaT).

[0074] Table 1. Cytotoxicity test results

[0075] The cytotoxicity test results of the liquid complex prepared in Example 1 are shown in Table 1. The volume percentages of the liquid complexes in test groups 1, 2, 3, 4, 5, 6, 7, and 8 are 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125%, respectively. The cell viability at volume percentages of 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125% were 94.27%, 90.45%, 87.73%, 87.79%, 87.41%, 84.84%, 87.27%, and 88.85%, respectively, all greater than 70%, indicating that the tested liquid complex was not cytotoxic. The cytotoxicity of the succinate derivative prepared in Example 2 was tested. The liquid complex was prepared using the method described in Example 2, but the succinate derivative was changed to 1 wt%. Then, it was added to the cell culture medium at a volume percentage of 2.50%, resulting in a cell viability of 92.51% and no cytotoxicity.

[0076] 2. Cell proliferation test

[0077] This invention tested the cell proliferation of the liquid complex prepared in Example 1. The liquid complex from Example 1 was mixed with culture medium to prepare eight test groups with different volume percentages: 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125%. A blank control group and a positive control group were set up. The blank control group consisted of culture medium, and the positive control group consisted of culture medium supplemented with 10% DMSO. The test groups, blank control group, and positive control group were brought into contact with test cells, and the cell proliferation rate of HSF cells was calculated to evaluate the effect on cell proliferation. The test cells were human skin fibroblasts (HSF).

[0078] Table 2. Results of cell proliferation assay

[0079] The cell proliferation test results of the liquid complex prepared in Example 1 are shown in Table 2. The volume percentages of the liquid complexes in test groups 1, 2, 3, 4, 5, 6, 7, and 8 are 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, 0.0390625%, and 0.01953125%, respectively. The test groups showed significant cell proliferation-promoting effects on human skin fibroblasts (HSF) at volume percentages of 2.50%, 1.25%, 0.625%, 0.3125%, 0.15625%, 0.078125%, and 0.0390625%.

[0080] 3. Anti-inflammatory effect test

[0081] This invention utilizes a Luminex 200 liquid chromatography-suspension microarray analyzer to detect the expression of inflammatory factors in human fibroblasts after treatment with test samples. Three different test samples were administered to human fibroblasts, and after culturing at 37°C in a CO2 incubator for 24 hours, the supernatant was collected into new plates for protein microarray analysis to detect the expression levels of cellular inflammatory factors. The above tests were divided into four groups, each containing three replicates: a negative control group, test group 1, test group 2, and test group 3. Water was added to the negative control group. Test group 1 consisted of 0.5 vol% of the liquid complex prepared in Example 1, test group 2 consisted of 0.5 vol% of commercially available product 1, and test group 3 consisted of 0.5 vol% of commercially available product 2. Commercially available product 1 was Winona Revitalizing Repair Essence, and commercially available product 2 was Helena Rubinstein Green Bottle Essence.

[0082] The expression of 48 inflammatory factors was detected in this study. The results are shown in Figures 1-3. The significance of the results of 8 inflammatory factors was analyzed, and the results are shown in Figure 4.

[0083] Table 3. Statistical table of significant inflammatory factors

[0084] The statistical significance of the eight inflammatory factors in this invention is shown in Table 3. Among them, test groups 1, 2, and 3 all showed a significant downregulation ability of CRO-α inflammatory factor expression. Through in-depth comparative research on the three types of skin care essence products, it was found that test group 1 had the most significant inhibitory effect on inflammation at 0.5 vol%.

[0085] This invention conducted anti-inflammatory tests on the liquid complexes prepared in Examples 1-5 and Comparative Examples 1-2, setting up a negative control group consisting of water. The expression of inflammatory factors in MIF was compared and analyzed, and the results are shown in Figure 5. In Figure 5, S1 represents Example 1, S2 represents Example 2, S3 represents Example 3, S4 represents Example 4, S5 represents Example 5, D1 represents Comparative Example 1, D2 represents Comparative Example 2, and NC represents the negative control group. This invention uses an active ingredient, an adjuvant, and water to prepare the liquid complex. The active ingredient includes at least an active ingredient, and the adjuvant includes a thickener, a humectant, and a preservative. The active ingredient can be at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposomes, bifida ferment lysate, and lysate. Through the combination of the active ingredient and the adjuvant, the resulting liquid complex exhibits good anti-inflammatory effects. An active ingredient can also be added to the active ingredient; the active ingredient in this invention can include amber. The succinate derivative is made from 2-aminoethanol hydrogen sulfate and maleate, which in turn is made from trimethylolpropane and maleic anhydride. The use of the succinate derivative, in combination with the active ingredient and excipients, results in a liquid complex with better anti-inflammatory activity and a better reduction effect on the relative expression level of MIF genes. Increasing the amount of succinate derivative increases the anti-inflammatory activity of the liquid complex, further reducing the relative expression level of MIF genes. If the amount of succinate derivative in the active ingredient is too low, it cannot enhance the anti-inflammatory activity of the liquid complex, nor can it reduce the relative expression level of MIF genes. In this invention, alginate-1,2-propanediol ester can also be added to the active ingredient. When alginate-1,2-propanediol ester and succinate derivative are used together as active ingredients and excipients, the resulting liquid complex has better anti-inflammatory activity and a better reduction effect on the relative expression level of MIF genes. If no active ingredient is used in the liquid complex, and only the active ingredient is added, the resulting liquid complex has poor anti-inflammatory activity and cannot significantly reduce the relative expression level of MIF genes.

[0086] 4. Quantitative gene expression test for anti-aging effects

[0087] This invention employs the Luminex 200 suspension chip multiplex detection system technology, combined with the QGP method, to detect and analyze the effects of three test samples on gene expression in human fibroblasts. This invention uses three different test samples to administer to HFF cells, at a ratio of 8 × 10⁸ cells per well. 4 Cells were seeded at a density of 0.5 ml per well in a 24-well plate. The cells were then incubated in an incubator for 24 hours.

[0088] In this invention, the above tests were divided into four groups, each containing three replicates: a negative control group, test group 1, test group 4, and test group 5. Water was added to the negative control group. Test group 1 contained 0.5 vol% of the liquid complex prepared in Example 1; test group 4 contained 0.5 vol% of commercially available product 3; and test group 5 contained 0.5 vol% of commercially available product 4. Commercially available product 1 was Winona Revitalizing Repair Essence, and commercially available product 2 was Helena Rubinstein Green Bottle series essence. Both contained 0.5 vol%. After 24 hours of incubation, the supernatant was removed, and 0.2 ml of cell lysis buffer was added to the wells containing HFF cells to lyse the cells. The lysed cells were stored at -80°C. Commercially available product 4 was a certain W essence, and commercially available product 5 was Helena Rubinstein Green Bottle series essence.

[0089] This invention detected the expression of 41 genes using three different cell sample treatments. The results for the entire genome are shown in Figures 6-8. Significance analysis was performed on eight genes: COL3A1, COL1A1, FGF7, TIMP2, SOD2, NFE2L2, MMP1, and IL6. The results are shown in Figure 9 and Table 4.

[0090] Table 4. Results of significance analysis of seven genes.

[0091] The 0.5 vol% test group 1 significantly upregulated the relative expression levels of COL3A1, COL1A1, and NFE2L2 genes (p<0.01), significantly upregulated the relative expression levels of FGF7 and TIMP2 genes (p<0.05), and significantly downregulated the relative expression level of MMP1 gene (p<0.01); the 0.5 vol% test group 5 significantly upregulated the relative expression level of COL1A1 gene (p<0.01).

[0092] In summary, among test groups 1, 4 and 5, test group 1 showed the best regulatory effect on aging genes and had a significant anti-aging ability.

[0093] This invention tested the anti-aging effects of the liquid complexes prepared in Examples 1-5 and Comparative Examples 1-2, with a negative control group consisting of water. The relative expression levels of the NFE2L2 gene were compared and analyzed, and the results are shown in Figure 10. In Figure 10, S1 represents Example 1, S2 represents Example 2, S3 represents Example 3, S4 represents Example 4, S5 represents Example 5, D1 represents Comparative Example 1, D2 represents Comparative Example 2, and NC represents the negative control group. This invention uses an active ingredient, an adjuvant, and water to prepare the liquid complex. The active ingredient includes at least an active ingredient, and the adjuvant includes a thickener, a humectant, and a preservative. The active ingredient can be at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, ACE liposomes, bifida ferment lysate, and lysate. Through the combination of the active ingredient and the adjuvant, the resulting liquid complex exhibits good anti-aging effects. An active ingredient can also be added to the active ingredient; the active ingredient in this invention can include succinate derivatives. The succinate derivative is made from 2-aminoethanol hydrogen sulfate and maleate, which is made from trimethylolpropane and maleic anhydride. The use of the succinate derivative, in combination with the active ingredient and excipients, results in a liquid complex with better anti-aging ability and a better effect on increasing the relative expression level of the NFE2L2 gene. Increasing the amount of succinate derivative increases the anti-aging ability of the liquid complex and can increase the relative expression level of the NFE2L2 gene. If the amount of succinate derivative in the active ingredient is too low, it cannot enhance the anti-aging ability of the liquid complex, nor can it increase the relative expression level of the NFE2L2 gene. Furthermore, alginate-1,2-propanediol ester can be added to the active ingredient of this invention. When alginate-1,2-propanediol ester and succinate derivative are used together as active ingredients and excipients, the resulting liquid complex has better anti-aging ability and a better effect on increasing the relative expression level of the NFE2L2 gene. If no active ingredient is used in the liquid complex, but only an active agent is added, the resulting liquid complex will not have good anti-aging ability and will not be able to significantly increase the relative expression level of NFE2L2 gene.

[0094] 5. Human skin patch test

[0095] Using the 2015 Cosmetic Safety Technical Specifications as a reference standard, the liquid complex prepared in Example 1 was used as a test sample for skin-residual products to evaluate the irritation of cosmetics. The test method was a skin patch test, and 30 people aged 18-60 years were randomly distributed to participate in the test.

[0096] Test method: Place the test sample into a patch applicator (0.025g). Cover the patch applicator with non-irritating adhesive tape and apply it to the flexor side of the subject's forearm. Gently press with the palm to ensure even adhesion to the skin surface. Leave on for 24 hours. Remove the patch applicator and observe the skin reaction 30 minutes after the pressure mark disappears. If the result is negative, observe again at 24 and 48 hours after the patch test.

[0097] Evaluation criteria:

[0098] Grade 0: Negative reaction;

[0099] Grade 1: Suspicious reaction, with only slight erythema;

[0100] Grade 2: Weak positive reaction, erythema, infiltration, edema, and possible papules;

[0101] Grade 3: Strong positive reaction, erythema, infiltration, edema, papules may be present, and the reaction may extend beyond the test area;

[0102] Grade 4: Extremely positive reaction, with obvious erythema, severe infiltration, edema, confluent herpes, and reaction extending beyond the test area.

[0103] Test results: All subjects had negative skin reactions.

[0104] The above test results show that the liquid complex prepared by the present invention is gentle and non-irritating to the skin and safe to use as a skin-residing product.

[0105] 6. Anti-inflammatory effect test after cosmetic surgery

[0106] Thirty volunteers, aged 20-50, were recruited for post-procedure cosmetic procedures such as IPL and hyaluronic acid injections. The liquid complex prepared in Example 1 was used as a test sample three days after the procedure. After cleansing the face, the test sample was evenly applied and used continuously for 28 days. Skin condition was observed on days 0, 14, and 28.

[0107] Test metrics:

[0108] 6.1. TEWL value test: TEWL refers to the transepidermal water loss and stratum corneum water content of the face. The lower the value, the higher the stratum corneum water content and the better the skin barrier function; conversely, the higher the value, the worse the skin barrier function.

[0109] TEWL value: Healthy state (0 15), Sub-healthy state (15 25), Disease state (>25).

[0110] Table 5. TEWL Value Detection Results

[0111] After 28 days of use of the test product, the subjects experienced a highly significant reduction in transdermal water loss. This indicates that continuous use of the test product significantly improved transdermal water loss compared to the initial value, with an improvement rate of 12.25%.

[0112] 6.2 Heme Level Detection: The heme content in the skin is determined by measuring the amount of light reflected from the skin at a specific wavelength. The lower the heme content, the lighter the redness.

[0113] Table 6. Results of Heme Level Detection

[0114] After 28 days of use of the test product, the subjects' heme levels showed a highly significant decrease. This indicates that continuous use of the test product improved heme levels compared to the initial value. The improvement rate was 6.05%.

[0115] 6.3. Feedback on adverse reactions during use

[0116] All 30 participants used the test product as required within the specified time, and no adverse reactions occurred.

[0117] The embodiments and / or implementation methods described above are merely preferred embodiments and / or implementation methods for implementing the technology of the present invention, and are not intended to limit the implementation methods of the technology of the present invention in any way. Any person skilled in the art can make some modifications or alterations to other equivalent embodiments without departing from the scope of the technical means disclosed in the content of the present invention, but they should still be regarded as the technology or embodiments that are substantially the same as the present invention.

[0118] This document uses specific examples to illustrate the principles and implementation methods of this application. The descriptions of the above embodiments are only for the purpose of helping to understand the methods and core ideas of this application. The above descriptions are only preferred embodiments of this application. It should be noted that due to the limitations of written expression, while there are objectively infinite specific structures, those skilled in the art can make several improvements, modifications, or changes without departing from the principles of this application, and can also combine the above technical features in an appropriate manner. These improvements, modifications, changes, or combinations, or the direct application of the inventive concept and technical solution to other situations without modification, should all be considered within the scope of protection of this application.

Claims

1. A liquid complex comprising: The active ingredient and water, wherein the content of the active ingredient in the liquid complex is 0.003-6.0 wt%; the active ingredient includes an active ingredient, which includes at least one of acetyl hexapeptide-8, oligopeptide-1, snake venom-like peptide, carnosine, palmitoyl tripeptide-1, palmitoyl tripeptide-5, ACE liposomes, Bifida ferment lysate and lysate. The active agent also includes an activator, which includes succinate derivatives and 1,2-propanediol alginate. In the preparation of succinate derivatives, sodium hydroxide and 2-aminoethanol hydrogen sulfate are added to deionized water and stirred. Then, maleate and ethanol are added at 30-50℃ and reacted for 2-8 hours. After the reaction is complete, the precipitate is cooled and precipitated. The precipitate is filtered, washed, and distilled under reduced pressure to obtain the succinate derivative. The amount of sodium hydroxide used is 30-50 wt% of deionized water, the amount of 2-aminoethanol hydrogen sulfate used is 40-60 wt% of deionized water, the amount of 2-aminoethanol hydrogen sulfate used is 20-30 wt% of maleate, and the amount of anhydrous ethanol used is 100-200 wt% of maleate. In the preparation of maleic ester, trimethylolpropane is added to maleic anhydride at 60-80℃ and reacted at 85-95℃ for 2-8 hours. After the reaction is completed, maleic ester is obtained. The amount of trimethylolpropane used is 50-150 wt% of maleic anhydride. The content of the active agent in the liquid complex is 0.003-1.0 wt%; or, the content of the active ingredient in the liquid complex is 0.003-5.0 wt%.

2. The liquid composite according to claim 1, characterized in that: The liquid complex further includes a thickener, which includes at least one of carbomer, xanthan gum, and sclerotinia gum, and the content of the thickener in the liquid complex is 0.01-1.0 wt%.

3. The liquid composite according to claim 1, characterized in that: The liquid complex further includes a humectant, which includes at least one of glycerin, 1,2-pentanediol, 1,2-hexanediol, dipropylene glycol, carboxymethyl cellulose, and chitosan, and the content of the humectant in the liquid complex is 1-20 wt%.

4. A liquid composite according to claim 1, characterized in that: The liquid complex also includes a preservative, which is a raspberry ketone system, and the content of the preservative in the liquid complex is 0.1-1.0 wt%.

5. Use of any one of the liquid complexes according to claims 1-4 in the preparation of anti-inflammatory cosmetics and / or anti-aging cosmetics and / or non-irritating products.

6. The use according to claim 5, characterized in that: The liquid complex also contains at least one of EDTA, disodium EDTA, and an amino acid.

Images